Pharmafile Logo

PHARMA POST COVID-19: REVOLUTION OR EVOLUTION?

- PMLiVE

Post-COVID-19 thinking: outputs from a thought leader forum

On 14 May 2020, a group of industry experts across pharma and biotech Zoomed together to share reflections on the impact of COVID-19 so far and the implications for how we should evolve in the coming months and years:
Download full article here

EXECUTIVE SUMMARY

Biggest impact of COVID-19

  • COVID-19 has had a significant impact on how the industry works; maintaining individuals’ well-being and finding the best ways to integrate digital has challenged many companies
  • Clinical trials have been affected, in particular, recruitment and progress. It was also noted that certain metrics and data collection are likely to be affected and may have an impact on future regulatory submissions
  • Our forum concluded that in general we expect sales of established medicines to be above expectations, with newer therapies likely to be behind budget, due mainly to patients not attending clinic and a reduced new/switched/repeat dynamic

Biggest concerns

  • We highlighted concern that future pricing may be affected. Government debt has been affected by COVID-19 and this may impact future pricing negotiations and also see a quicker transition to outcomes-based pricing
  • Our recommendation is that the industry needs to continue to build trust. Vaccine and COVID-19 treatment costs will be high-profile negotiations and may affect reputation or profits.
  • There is an opportunity for the industry to transition its reputation from medicines developers to healthcare providers
  • The industry needs to evolve how it works digitally, but we don’t expect a revolution, rather a gradual upskilling of organisations and of its people to enable more effective working. How this is done, however, is still uncertain, and is an opportunity for better collaboration

Biggest opportunities

  • We concluded that re-shaping how the field force evolve and work is a huge opportunity for the industry to add more value to society. How to add value through a truly multi-channel approach is an exciting opportunity for our industry, and a key opportunity for future discussion
  • The industry has spent millions on congress attendance for so many years. How the industry has recently operated offers an opportunity to re-think how to engage with congresses, but more importantly how to engage with healthcare professionals throughout the year. We don’t see a time when congresses are not important, but whether medical communications are anchored to congresses in the future is an opportunity to explore
  • It’s difficult to predict the new normal, but we know digital and user experience will be critical to effective commercialisation. This provides an exciting opportunity for our industry to create compelling digital experiences for brand and organisations to communicate with their audiences
  • We expect increased pricing pressure in the future. The organisations that adapt best, by providing real-world evidence, outcomes-based evidence and pricing, and support service re-design, will lead the future industry

Download full article here

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Lucid Learning and Development

Julieann Tate, Head of hashtagLearning and Development at Lucid Group, discusses the new programmes and tools she has been busy developing and rolling out throughout the organisation — Elevating employee...

Lucid Learning and Development

Julianne Tate, Head of Learning and Development at Lucid Group, discusses the new programmes and tools that she has been busy developing and rolling out throughout the Group — Elevating...

Lucid Group Announce Neil Flash as its New Chief Commercial Officer

With over 20 years’ healthcare communications experience, Neil Flash joins Lucid Group as its Chief Commercial Officer to help lead the organisation through another exciting period of growth.

My Journey into Medical Communications #LucidLife

In NetworkPharma's latest career guide for wannabe account managers, our very own Aveen Hamid discusses her journey into medical communications and the opportunity to work on programmes that transform patients’...

Lucid Group adds more magic to the mix with four new hires

Leading Edge, a Lucid Group company, injects new talent into its client services and medical writing teams. Miranda Harrison joins the team as its Client Operations Director. Miranda is a...

Lucid Group expands its presence in the north-west with six new hires

Healthcare 21, a Lucid Group company, continues to strengthen its editorial and medical writing team with six new additions to its Macclesfield office.Rosanna Farrell joins HealthCare 21 as a Senior...

There’s lots to celebrate as Lighthouse marks its five year anniversary

Based in Manhattan, Lighthouse Medical Communications US has grown significantly over the last five years, both in terms of team and client roster. Lisa Druce, Managing Partner comments, “Every year,...

Lucid Group bolsters its client services and medical writing team in APAC

HealthCare21, a Lucid Group company, has appointed two new team members in its Singapore office — Siew Wyn and Megan Giliam.Wyn joins the team as a Senior Account Manager and...

Lucid Group kick starts its 2020 Futures Academy

It’s a new year and the start of a new career for the six graduates starting on Lucid’s Futures Academy this week.This is Lucid’s fourth intake of graduates since the...